Hepatocellular Cancer: Epidemiology and Patient-Based Market Forecasts, Treatment Algorithm, and Marketed and Pipeline Drug Analysis - Product Image

Hepatocellular Cancer: Epidemiology and Patient-Based Market Forecasts, Treatment Algorithm, and Marketed and Pipeline Drug Analysis

  • ID: 3797446
  • Drug Pipelines
  • 216 pages
  • Datamonitor Healthcare
1 of 3
The success of Nexavar has boosted the development of new targeted therapies, approvals of which will drive the growth of the hepatocellular cancer market.

This report addresses the following questions:

- Which products will drive the growth of the hepatocellular cancer market?
- What is the commercial potential for each drug in the late-stage pipeline for hepatocellular cancer?
- Which geographic markets have the largest populations of hepatocellular cancer patients and how does this impact each market’s value?
- What are the most common treatment settings within hepatocellular cancer being targeted by drug developers?
- Which pipeline products will actively compete with each other once they reach the market and how will they impact currently approved drugs?
Note: Product cover images may vary from those shown
2 of 3
FORECAST: HEPATOCELLULAR CANCER IN THE US, JAPAN, AND EU

- Executive Summary
- Market Overview and Trends
- Methodology and Market Definition
- ADI-PEG
- (PEG-arginine deiminase)
- Cometriq
- Nexavar (sorafenib)
- Ramucirumab
- Stivarga (regorafenib)
- tivantinib (ARQ 197)
- TS-1 (gimeracil/oteracil potassium/tegafur)
- Primary Research Methodology

TREATMENT: HEPATOCELLULAR CANCER

- Executive Summary
- Primary Research Methodology
- Disease Definition and Diagnosis
- Country Treatment Trees
- Patient Segmentation
- Current Treatment Options
- Prescribing Trends
- Future Changes in Therapy

EPIDEMIOLOGY: HEPATOCELLULAR CANCER IN THE US, JAPAN, AND 5EU

- Executive Summary
- Disease Background
- Sources and Methodology
- Forecast
- Epidemiologist Insight
- Strengths and Limitations

MARKETED DRUGS: HEPATOCELLULAR CANCER

- Executive Summary
- Product Overview
- Product profile: Nexavar

PIPELINE: HEPATOCELLULAR CANCER

- Executive Summary
- Clinical Pipeline Overview
- Target Product Profile
- Product profile (late stage): ADI-PEG
- Product profile (late stage): Cometriq
- Product profile (late stage): Cyramza
- Product profile (late stage): Lenvima
- Product profile (late stage): Stivarga
- Product profile (late stage): peretinoin
- Product profile (late stage): tivantinib
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll